Uromonitor®: Reducing Unnecessary Cystoscopies and TURBT Procedures

Non-muscle-invasive bladder cancer (NMIBC) follow-up relies on frequent cystoscopies, which are invasive, costly, and uncomfortable. Uromonitor® is a non-invasive urine test that detects NMIBC recurrence with high accuracy, significantly reducing unnecessary procedures.

Fewer Cystoscopies – Uromonitor® could have prevented 87.4% of unnecessary cystoscopies, reducing patient discomfort and healthcare costs.

Avoiding Unnecessary Surgeries – The test accurately identified 28 cases where TURBT was performed unnecessarily due to false-positive cystoscopies.

High Diagnostic Accuracy – With 89.7% sensitivity, 96.2% specificity, and a 98.8% negative predictive value (NPV), Uromonitor® offers a reliable alternative for NMIBC surveillance.

By minimizing unnecessary interventions, Uromonitor® enhances patient well-being while optimizing healthcare resources, making NMIBC follow-up more efficient and patient-friendly.

Read the full article